Rapport Therapeutics, Inc.
RAPP
$47.42
$0.060.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -111.79% | 17.48% | -68.98% | -53.53% | -47.52% |
| Total Depreciation and Amortization | -15.87% | -6.97% | 1.92% | 16.89% | 21.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 70.31% | 82.67% | 31.96% | 298.99% | 183.85% |
| Change in Net Operating Assets | 301.99% | -76.67% | 168.98% | 875.26% | -2,639.84% |
| Cash from Operations | -65.36% | 35.46% | -70.99% | -6.40% | -53.31% |
| Capital Expenditure | -254.55% | 70.45% | 25.22% | 4.29% | 97.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.68% | 78.35% | -641.59% | -7.07% | 121.31% |
| Cash from Investing | 13.29% | 80.41% | -645.96% | -7.04% | 121.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 13,383.33% | 4,342.86% | -- | -100.00% |
| Repurchase of Common Stock | -- | -400.00% | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -187.30% | -- | -- | -- | -122.26% |
| Cash from Financing | 2,339.68% | 10,520.00% | 4,342.86% | 19,506.96% | -100.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -469.33% | 3,080.35% | -1,236.09% | 377.05% | -107.07% |